Peptide News Digest

Silence $175M ADS Close, BridgeBio $406M Secondary, Retatrutide 2026/2027 Filing, Peptide CDMO Consolidation

Silence closes upsized $175M ADS offering. BridgeBio KKR $406M secondary at $81.21. Retatrutide FDA filing late 2026/2027. CDMO consolidation wave.

4 stories · Covering industry, clinical-trials

Editor's Note

Friday-Saturday's peptide-and-adjacent news centers on financing activity and the broader industry's manufacturing-consolidation wave. Silence Therapeutics (NASDAQ: SLN) closed its upsized $175 million public offering of American Depositary Shares (ADSs) following the Phase 2 SANRECO win last week: the offering priced at $13.50 per ADS on August 11 for 12,962,963 ADSs, and the underwriters (Jefferies, Morgan Stanley, Cantor, William Blair) fully exercised their 30-day overallotment option for an additional 1,944,444 ADSs bringing the total to 14,907,407 ADSs. BridgeBio Pharma (NASDAQ: BBIO) priced a 5-million-share secondary offering Friday August 14 on behalf of selling stockholder KKR Genetic Disorder L.P. at the August 13 closing price of $81.21 per share, implying roughly $406 million in proceeds to KKR; the offering is expected to close August 17 with William Blair, Goldman Sachs, and KKR Capital Markets as joint book-running managers. The BridgeBio commercial franchise includes infigratinib, the weekly-dosing achondroplasia FGFR inhibitor that competes directly with BioMarin's Voxzogo (vosoritide) and Ascendis's newly-launched YUVIWEL (TransCon CNP), and the pipeline continues to expand. Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon agonist) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026, positioning retatrutide for potential FDA approval in 2027-2028 as the highest-magnitude weight loss obesity drug at 28.7% at 68 weeks (TRIUMPH-4). And the broader peptide CDMO consolidation wave continues with Samsung Biologics' pending $1.8 billion acquisition of PolyPeptide Group (prospectus expected by end of August), the August 11 Gland Pharma / Neuland Laboratories long-term sterile API manufacturing partnership in Visakhapatnam, and continued capacity build-outs at Bachem and CordenPharma.

Industry

Silence Therapeutics (NASDAQ: SLN) Closed Its Upsized $175 Million Underwritten Public Offering of American Depositary Shares Following the August 10 Phase 2 SANRECO Trial Win in Polycythemia Vera Where Divesiran Achieved 88% Response Versus 19% on Placebo (P<0.0001, 69% Placebo-Adjusted Response Rate); The Offering Priced on August 11 at $13.50 per ADS for 12,962,963 ADSs and the Underwriters (Jefferies, Morgan Stanley, Cantor, and William Blair as Joint Book-Running Managers) Fully Exercised Their 30-Day Overallotment Option for an Additional 1,944,444 ADSs Bringing the Total to 14,907,407 ADSs; The Financing Provides the Capital to Advance Divesiran Into Phase 3 (Planned Initiation H1 2027) Plus Broader Pipeline Progression Including the GalNAc-Conjugated Hepatic-Target siRNA Portfolio Across TMPRSS6, Complement Component 3 (SLN-124/SLN-501), and Other Hepatic Targets

Silence Therapeutics (NASDAQ: SLN) closed its upsized $175 million underwritten public offering of American Depositary Shares (ADSs) following the August 10, 2026 Phase 2 SANRECO trial win in polycythemia vera. Trial anchor: divesiran achieved 88% response versus 19% on placebo (P<0.0001, 69% placebo-adjusted response rate) in 48 phlebotomy-dependent patients over 36 weeks. Offering mechanics: priced August 11 at $13.50 per ADS for 12,962,963 ADSs. The underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as joint book-running managers) fully exercised their 30-day overallotment option for an additional 1,944,444 ADSs, bringing the total offering to 14,907,407 ADSs and gross proceeds to approximately $175 million. The financing provides the capital to advance divesiran into Phase 3 (planned initiation H1 2027) plus broader pipeline progression including the GalNAc-conjugated hepatic-target siRNA portfolio across TMPRSS6, complement component 3 (SLN-124/SLN-501), and other hepatic and extrahepatic targets. Divesiran has FDA Fast Track and Orphan Drug designations for polycythemia vera; the transferable-voucher secondary market and the recently completed Arrowhead $215 million Priority Review Voucher purchase provide comparable references for the broader siRNA regulatory-instrument landscape.

#silence-therapeutics #sln #175-million-offering #public-offering-close #divesiran #sanreco #polycythemia-vera #sirna #tmprss6 #hepcidin #jefferies #morgan-stanley #phase-3-planning
Industry

BridgeBio Pharma (NASDAQ: BBIO) Priced a 5,000,000-Share Secondary Offering of Common Stock on Friday August 14, 2026 on Behalf of Selling Stockholder KKR Genetic Disorder L.P. at the August 13 Closing Price of $81.21 per Share, Implying Roughly $406 Million in Proceeds to KKR (BridgeBio Is Not Selling Any Shares and Will Not Receive Any of the Proceeds); The Offering Is Expected to Close August 17 With William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as Joint Book-Running Managers; The BridgeBio Commercial Franchise Includes Infigratinib, the Weekly-Dosing FGFR Inhibitor for Achondroplasia That Competes Directly Against BioMarin's Voxzogo (Vosoritide, Daily Subcutaneous CNP Analog) and Ascendis's Newly-Launched YUVIWEL (Weekly TransCon C-Type Natriuretic Peptide), Positioning the Company at the Center of the Newly Competitive Pediatric Achondroplasia Commercial Category

BridgeBio Pharma (NASDAQ: BBIO) priced a 5,000,000-share secondary offering of common stock on Friday August 14, 2026 on behalf of selling stockholder KKR Genetic Disorder L.P. at the August 13 closing price of $81.21 per share on Nasdaq. The implied secondary-market proceeds to KKR total roughly $406 million. BridgeBio is not selling any shares and will not receive any of the proceeds; the transaction diversifies BridgeBio's institutional shareholder base as KKR reduces its position following a multi-year holding period. The offering is expected to close August 17, 2026 with William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as joint book-running managers. The BridgeBio commercial franchise includes infigratinib, the weekly-dosing FGFR inhibitor for achondroplasia that competes directly against BioMarin's Voxzogo (vosoritide, daily subcutaneous C-type natriuretic peptide analog) and Ascendis's newly-launched YUVIWEL (weekly TransCon C-type natriuretic peptide). The three-way competitive dynamic in pediatric achondroplasia now involves daily-injectable (Voxzogo), weekly-injectable peptide (YUVIWEL), and weekly-oral small-molecule (infigratinib) options, and the BridgeBio franchise is positioned at the small-molecule end of that spectrum. Although infigratinib is not itself a peptide analog, the achondroplasia commercial category is one of the fastest-growing peptide-adjacent pediatric-rare-disease indications following the July 8, 2026 New England Journal of Medicine publication of the Ascendis TRANSCEND trial results and the June 2026 YUVIWEL FDA approval.

#bridgebio-pharma #bbio #kkr-genetic-disorder #406-million-secondary #infigratinib #achondroplasia #voxzogo #biomarin #ascendis-pharma #yuviwel #transcon-cnp #5-million-shares #81-21-price
Clinical Trials

Eli Lilly (NYSE: LLY) Is Expected to Submit Retatrutide (Once-Weekly Injectable Triple GLP-1/GIP/Glucagon Receptor Agonist Peptide) to the FDA in Late 2026 or 2027 Following the Seven Phase 3 TRIUMPH-Program Readouts Expected Across 2026 (Including TRIUMPH-1 in Obesity Meeting Primary Endpoint With 28.7% Mean Weight Loss at 68 Weeks at the 12 mg Dose, TRIUMPH-4 in Obesity Plus Knee Osteoarthritis Documenting 28.7% Weight Loss and 75.8% Reduction in WOMAC Pain Scores With More Than 1 in 8 Retatrutide-Treated Patients Completely Free From Knee Pain, and Additional Readouts in Type 2 Diabetes, Obstructive Sleep Apnea, and Cardio-Renal-Metabolic Indications); Potential FDA Approval Expected in 2027-2028 Would Position Retatrutide as the Highest-Magnitude Weight Loss Obesity Drug

Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon receptor agonist peptide) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026. Program status: TRIUMPH-1 in obesity met primary endpoint with 28.7% mean weight loss at 68 weeks at the 12 mg dose; TRIUMPH-4 in obesity plus knee osteoarthritis documented 28.7% weight loss and 75.8% reduction in WOMAC pain scores with more than 1 in 8 retatrutide-treated patients completely free from knee pain at study end. Additional Phase 3 readouts expected across 2026 in type 2 diabetes, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic indications. If the full TRIUMPH package supports approval, retatrutide would be the highest-magnitude weight loss obesity drug on record (extending the ceiling from tirzepatide's 25.5% at 84 weeks in REDEFINE 4 head-to-head to 28.7% in TRIUMPH-4). The triple-receptor mechanism activates GLP-1 (appetite suppression via hypothalamic pathways), GIP (adipose tissue effects plus central appetite contribution), and glucagon (hepatic effects plus thermogenesis), producing broader tissue coverage than dual-agonist tirzepatide or amylin-plus-GLP-1 CagriSema. Approval is anticipated in 2027-2028 and would reshape the competitive dynamics for the entire obesity drug class, with substantial implications for Novo Nordisk's franchise defense strategy following the August 2026 broker downgrade and Wegovy 7.2 mg higher-dose FDA review submission.

#eli-lilly #lly #retatrutide #triple-agonist #glp-1-gip-glucagon #triumph-program #triumph-1 #triumph-4 #28-7-percent-weight-loss #womac-pain-reduction #phase-3 #fda-submission-2026-2027 #highest-magnitude-weight-loss
Industry

The Broader Peptide CDMO Consolidation Wave Continues Across August 2026 With Samsung Biologics' Pending $1.8 Billion All-Cash Tender Offer for PolyPeptide Group AG at CHF 44.31 per Share (Prospectus Expected by End of August, Closing Toward End of 2026), the August 11 Gland Pharma and Neuland Laboratories Long-Term Sterile API Manufacturing Partnership in Visakhapatnam India, and Continued Capacity Build-Outs at Bachem, CordenPharma, and AmbioPharm Positioning the Peptide CDMO Industry for the Multi-Billion-Dollar Demand Wave From Semaglutide and Tirzepatide Commercial-Scale API Plus Retatrutide, Amycretin, VK2735, Ribupatide, and Next-Generation Combination Peptide Phase 3 Programs

The broader peptide contract development and manufacturing organization (CDMO) consolidation wave continues across August 2026 with three concurrent developments. First, Samsung Biologics' pending $1.8 billion all-cash tender offer for PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion total equity value, 40% premium to undisturbed share price) advances toward closing: the formal tender offer prospectus is expected to be published by end of August 2026 following Draupnir Holding B.V. (55.65% stake) commitment to tender and PolyPeptide's Board of Directors unanimous recommendation, with closing expected toward end of 2026. Second, Gland Pharma and Neuland Laboratories announced August 11, 2026 a long-term sterile API manufacturing partnership in Visakhapatnam, India, extending India's growing role as a peptide API manufacturing hub. Third, Bachem, CordenPharma, and AmbioPharm continue capacity build-outs. Collective capacity positioning targets the multi-billion-dollar demand wave from semaglutide and tirzepatide commercial-scale API (roughly $17 billion combined active pharmaceutical ingredient market by 2028 per industry estimates) plus retatrutide, amycretin, VK2735, ribupatide, and next-generation combination peptide Phase 3 programs. The consolidation trajectory suggests peptide CDMO capacity concentration among a smaller number of large operators through the end of the decade, with the Samsung acquisition of PolyPeptide as the anchor transaction.

#peptide-cdmo #peptide-manufacturing #samsung-biologics #polypeptide-group #gland-pharma #neuland-laboratories #bachem #cordenpharma #ambiopharm #cdmo-consolidation #sterile-api #semaglutide-tirzepatide-api #17-billion-market